SAN DIEGO, April 11, 2016 /PRNewswire/ -- Molecular Stethoscope, Inc., a company developing novel blood-based early detection and disease monitoring tests, announced today that it has organized collaborations with 23 academic and medical institutions nationwide to address some of the most challenging scientific questions concerning diagnosis and monitoring of disease in patients.
San Diego-based Molecular Stethoscope has developed proprietary technology that utilizes circulating cell-free RNA in blood to monitor organ damage. This unique approach provides a real-time "snapshot" of organ health using RNA to represent the patient's actual and immediate phenotype (physical and biochemical characteristics), allowing for a more dynamic assessment of healthy versus diseased states. The Company's rapid, accurate and non-invasive tests will potentially revolutionize diagnosis and drug development for a variety of diseases that have thus far resisted management.
"Molecular Stethoscope's collaborations will allow us to gain valuable information about disease states through analysis of blood from a wide spectrum of disease stages and conditions," noted Tina S. Nova, Ph.D., President & CEO of the Company.
As part of the first phase of this collaboration, Molecular Stethoscope has received over 700 plasma and serum patient samples from its collaborators to continue validation of its cell-free circulating RNA-based molecular diagnostics. Samples from patients with Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease, Huntington's Disease, ALS (Lou Gehrig's Disease), and Nonalcoholic Fatty Liver Disease will be used to provide insights into these diseases and their impact on the cell-free transcriptome, RNA sequences that change in response to a particular condition or treatment.
"We are honored to work with renowned institutions across the U.S. to further our development of clinically actionable tests to improve patient health," said Jonathan Aballi, Head Laboratory Operations at Molecular Stethoscope.
About Molecular Stethoscope, Inc.
Molecular Stethoscope is taking groundbreaking insights and applying them to patient health. The Company has developed technology originating in the laboratories of Dr. Stephen Quake, Stanford University, and Dr. Eric Topol, Scripps Health, that will provide early detection and disease monitoring in critical and often hard-to-detect areas, including:
Coronary artery disease
Autoimmune and Inflammatory diseases
Molecular Stethoscope spans a multibillion dollar market opportunity that can ultimately lower healthcare costs by allowing earlier intervention in disease.